Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Arcutis Biotherapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

WESTLAKE VILLAGE, CALIF., AUG. 08, 2025 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY REPORTED THE GRANT OF AN AGGREGATE OF 21,000 RESTRICTED STOCK UNITS OF ARCUTIS' COMMON STOCK TO THREE NEWLY HIRED EMPLOYEES.

ARCUTIS BIOTHERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

Q2 2025 NET PRODUCT REVENUE FOR ZORYVE (ROFLUMILAST) WAS $81.5 MILLION, A 164% INCREASE COMPARED TO Q2 OF 2024, AND A 28% INCREASE COMPARED TO Q1 OF 2025, DRIVEN BY STRONG PORTFOLIO DEMAND GROWTH ZORYVE FOAM 0.3% RECEIVED U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVAL FOR THE TREATMENT OF PLAQUE PSORIASIS OF THE SCALP AND BODY IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER INITIATED INTEGUMENT-INFANT STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ZORYVE CREAM 0.05% IN INFANTS WITH ATOPIC DERMATITIS AGES 3 MONTHS TO 24 MONTHS SUBMITTED INVESTIGATIONAL NEW DRUG APPLICATION (IND) FOR ARQ-234, A NOVEL FUSION PROTEIN FOR THE POTENTIAL TREATMENT OF PATIENTS WITH ATOPIC DERMATITIS WESTLAKE VILLAGE, CALIF., AUG. 06, 2025 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY REPORTED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE30, 2025, AND PROVIDED A BUSINESS UPDATE.

ARCUTIS ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

ARCUTIS ANNOUNCED TODAY THAT IT WILL REPORT Q2 2025 FINANCIAL RESULTS AND PROVIDE A BUSINESS UPDATE ON AUG 6, 2025 AFTER THE U.S. FINANCIAL MARKETS CLOSE.

ARCUTIS TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON AUGUST 6, 2025

WESTLAKE VILLAGE, CALIF., JULY 03, 2025 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC.(NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY REPORTED THE GRANT OF AN AGGREGATE OF 14,000 RESTRICTED STOCK UNITS OF ARCUTIS' COMMON STOCK TO TWO NEWLY HIRED EMPLOYEES. THESE AWARDS WERE APPROVED BY THE COMPENSATION COMMITTEE OF ARCUTIS' BOARD OF DIRECTORS AND GRANTED UNDER THE ARCUTIS BIOTHERAPEUTICS, INC. 2022 INDUCEMENT PLAN, WITH A GRANT DATE OF JULY 1, 2025, AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH ARCUTIS, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

THE AMERICAN ACADEMY OF DERMATOLOGY (AAD) PROVIDED EVIDENCE-BASED RECOMMENDATION FOR THE USE OF ZORYVE (ROFLUMILAST) CREAM 0.15% IN ADULTS WITH MILD TO MODERATE ATOPIC DERMATITIS (AD) RECOMMENDATION REFLECTS ZORYVE'S PROVEN EFFICACY, SAFETY, AND TOLERABILITY AS A NEXT-GENERATION, STEROID-FREE, TOPICAL PHOSPHODIESTERASE-4 (PDE4) INHIBITOR AMONG NEWLY EVALUATED BRANDED TOPICAL THERAPIES, ZORYVE IS THE ONLY TREATMENT WITH A STRONG RECOMMENDATION FOR ADULTS WITH MILD TO MODERATE ATOPIC DERMATITIS IN AAD'S FOCUSED GUIDELINE UPDATE ZORYVE IS THE FIRST FDA-APPROVED BRANDED TOPICAL PDE4 INHIBITOR INDICATED FOR AD, PLAQUE PSORIASIS, AND SEBORRHEIC DERMATITIS AD IMPACTS OVER 16 MILLION ADULTS IN THE UNITED STATES WESTLAKE VILLAGE, CALIF, JUNE 26, 2025 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEDICATED TO DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY ANNOUNCED THAT ZORYVE (ROFLUMILAST) CREAM 0.15% HAS RECEIVED A STRONG RECOMMENDATION IN THE FOCUSED GUIDELINE UPDATE FOR THE MANAGEMENT OF ADULT AD FROM AAD. THE RECOMMENDATION HIGHLIGHTS ZORYVE'S ABILITY TO DELIVER CLINICALLY MEANINGFUL IMPROVEMENTS IN PRURITUS AND DISEASE SEVERITY, ITS FAVORABLE TOLERABILITY PROFILE, AND LOW RATES OF TREATMENT DISCONTINUATION, OFFERING ADULTS AND PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER WITH MILD TO MODERATE AD AN EFFECTIVE, NON-STEROID OPTION FOR DAILY DISEASE MANAGEMENT.

ARCUTIS' ZORYVE (ROFLUMILAST) CREAM 0.15% RECEIVES STRONG RECOMMENDATION IN AMERICAN ACADEMY OF DERMATOLOGY UPDATED GUIDELINES FOR ADULT ATOPIC DERMATITIS

FOUR-WEEK PHASE 2 STUDY TO EVALUATE INVESTIGATIONAL, ONCE-DAILY ZORYVE .05% IN INFANTS AS YOUNG AS 3 MONTHS TO LESS THAN 2 YEARS WITH ATOPIC DERMATITIS ATOPIC DERMATITIS IMPACTS 9.6 MILLION CHILDREN IN THE UNITED STATES; UP TO 60% OF CHILDREN WITH ATOPIC DERMATITIS DEVELOP SYMPTOMS WITHIN THEIR FIRST YEAR WESTLAKE VILLAGE, CALIF., JUNE 10, 2025 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY ANNOUNCED THAT THE FIRST CHILD HAS BEEN ENROLLED IN A PHASE 2 OPEN-LABEL STUDY, INTEGUMENT-INFANT, EVALUATING THE SAFETY AND TOLERABILITY OF INVESTIGATIONAL ZORYVE (ROFLUMILAST) CREAM 0.05% IN INFANTS AGED 3 MONTHS TO LESS THAN 24 MONTHS WITH ATOPIC DERMATITIS (AD) APPLIED ONCE DAILY OVER A FOUR-WEEK PERIOD.

ARCUTIS ENROLLS FIRST CHILD IN INTEGUMENT-INFANT EVALUATING ZORYVE (ROFLUMILAST)CREAM 0.05% IN INFANTS WITH ATOPIC DERMATITIS

WESTLAKE VILLAGE, CALIF., JUNE 06, 2025 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY REPORTED THE GRANT OF AN AGGREGATE OF 72,000 RESTRICTED STOCK UNITS OF ARCUTIS' COMMON STOCK TO NINE NEWLY HIRED EMPLOYEES. THESE AWARDS WERE APPROVED BY THE COMPENSATION COMMITTEE OF ARCUTIS' BOARD OF DIRECTORS AND GRANTED UNDER THE ARCUTIS BIOTHERAPEUTICS, INC. 2022 INDUCEMENT PLAN, WITH A GRANT DATE OF JUNE 2, 2025, AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH ARCUTIS, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

NEW DATA FROM THE PHASE 3 INTEGUMENT-OLE LONG-TERM OPEN LABEL STUDY SHOW DURABLE IMPROVEMENT IN THE SIGNS AND SYMPTOMS OF ATOPIC DERMATITIS (AD), INCLUDING ALMOST HALF OF PARTICIPANTS ACHIEVING NO OR MINIMAL ITCH WITH ZORYVE CREAM 0.15% OR ZORYVE CREAM 0.05% NEW DATA DEMONSTRATE THAT FOR CHILDREN AGES 2 TO 5 WHO ACHIEVED DISEASE CLEARANCE AND SWITCHED TO PROACTIVE TWICE-WEEKLY APPLICATION OF INVESTIGATIONAL ZORYVE CREAM 0.05%, THE MEDIAN DURATION OF DISEASE CONTROL WAS 238 DAYS CONSISTENT EFFICACY, SAFETY, AND TOLERABILITY PROFILE OBSERVED WITH ZORYVE CREAM WESTLAKE VILLAGE, CALIF., JUNE 06, 2025 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY ANNOUNCED THAT IT WILL PRESENT FIVE POSTERS AT THE 2025 REVOLUTIONIZING ATOPIC DERMATITIS (RAD) CONFERENCE, WHICH IS TAKING PLACE IN NASHVILLE, TN, FROM JUNE 6-7, 2025.

ARCUTIS TO PRESENT NEW LONG-TERM RESULTS OF ZORYVE (ROFLUMILAST) CREAM AT THE 2025 REVOLUTIONIZING ATOPIC DERMATITIS CONFERENCE

WESTLAKE VILLAGE, CALIF., MAY 29, 2025 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC.(NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY ANNOUNCED THAT ARCUTIS MANAGEMENT WILL PARTICIPATE IN THE GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE, TAKING PLACE JUNE 9-11, 2025.

ARCUTIS TO PRESENT AT THE GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

ONCE-DAILY ZORYVE FOAM PROVIDES POWERFUL CLEARANCE AND RAPID ITCH RELIEF FROM HEAD TO TOE WITH NO LIMITATION ON DURATION OF USE MORE THAN HALF OF THE NEARLY 9 MILLION PEOPLE IN THE UNITED STATES WITH PLAQUE PSORIASIS EXPERIENCE SCALP INVOLVEMENT HEALTHCARE PROVIDERS AND INDIVIDUALS WITH PLAQUE PSORIASIS CAN NOW CHOOSE ZORYVE FOAM OR CREAM TO TREAT PLAQUE PSORIASIS ANYWHERE IT APPEARS ON THE BODY FIFTH FDA APPROVAL FOR ZORYVE IN LESS THAN THREE YEARS MANAGEMENT WILL HOST AN INVESTOR EVENT WITH A KEY OPINION LEADER ON MONDAY, JUNE 2 AT 8:00 AM ET/5:00 AM PT WESTLAKE VILLAGE, CALIF., MAY 22, 2025 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY ANNOUNCED THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED THE SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) FOR ZORYVE (ROFLUMILAST)TOPICAL FOAM 0.3% FOR THE TREATMENT OF PLAQUE PSORIASIS OF THE SCALP AND BODY IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER.

Arcutis Biotherapeutics, Inc.

ARQT

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Arcutis Biotherapeutics, Inc.

ARQT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ARQT